| Clinical data | |
|---|---|
| Trade names | Regranex |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a699049 |
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
 N Y (what is this?) (verify) | |
Becaplermin (brand name Regranex) is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers.[1] It is also known as "platelet-derived growth factor BB".[1]
The drug is used for the treatment of diabetic foot ulcers.[2] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.[3] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.[4]
The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator.[1] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [5]
Becaplermin must not be used at the site of a skin cancer.[6]
The most common side effects in clinical studies were erythematous rashes.[6]
Aboxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used.[7] Regranex should be used with caution in patients with known malignancy.[1]
|
| |
|---|---|
| Cicatrizants |
|
| Proteolytic enzymes |
|
